论文部分内容阅读
作者对德国急性淋巴细胞白血病(ALL)多中心研究组1986～1990年治疗的复发性和难治性成人ALL 进行评价。66例患者年龄16～62(中数26.5)岁,男49例,女性17例。以前均接受过长春新碱、柔红霉素、天门冬酰胺酶、强的松、6巯嘌呤和阿糖胞苷等的治疗。再诱导化疗分两阶段进行。第一阶段:强的松60mg/m~2/日,1～21天;长春碱酰胺3mg/m~2/日,第1、8、15天;柔红霉素45mg/m~2/日,第1、8、15天;欧文菌属天门冬酰胺酶1000U/m~2/日,第7、8、14、15天。第一阶段治疗结束后仍有残余幼稚细胞浸润的患者,接受第二阶段诱导化疗:阿糖胞苷3.0mg/m~2/次(年龄>50岁者为1.0g/m~2/次),2次/日,1～4天;鬼臼乙叉甙100mg/m~2/日,1～5天。完全缓解(CR)患者接受巩固化疗。
The authors evaluated the relapsed and refractory adult ALL treated by the German multicenter study group of acute lymphoblastic leukemia (ALL) from 1986 to 1990. 66 patients aged 16 to 62 (median 26.5) years old, 49 males and 17 females. Previously received treatment of vincristine, daunorubicin, asparaginase, prednisone, 6-purine and cytarabine. Re-induction chemotherapy was performed in two phases. The first stage: prednisone 60 mg/m 2/day, 1 to 21 days; vinblastine base 3 mg/m 2/day, days 1, 8 and 15; daunorubicin 45 mg/m 2/day Days 1, 8, and 15; Owenella asparaginase 1000 U/m~2/day, 7, 8, 14, 15 days. Patients with residual infant cells infiltrated after the first phase of treatment received second-stage induction chemotherapy: cytarabine 3.0 mg/m~2/times (1.0 g/m~2/times for those over 50 years of age). , 2 times / day, 1 to 4 days; Erythropophanine ytterbium 100mg/m ~ 2 / day, 1 to 5 days. Patients with complete remission (CR) undergo consolidation chemotherapy.